Represented Liminatus Pharma, Inc. in its business combination with Iris Acquisition Corp

Represented Liminatus Pharma, Inc. (Nasdaq: LIMN), a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies, in its business combination with Iris Acquisition Corp, a special purpose acquisition company, for an aggregate enterprise value of $175 million.